1120 Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients With Obesity: A Pilot Study

View at publisher Summarise with VIRAT
Authors: Braeden Christopher Benedict, Aryan Pradhan, Dyan White-Gilliam, Salim M. Yakdan, Lucas Budd, Nathan Xu, Mikayla Gregory, Muhammad Irfan Kaleem, Noah Poulin, Abby L. Cheng, Susan Robinson Reeds, Goodin Burel
+1 more Jacob K. Greenberg
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Obesity is a known risk factor for degenerative disk disease and chronic low back pain (cLBP), yet research on weight loss interventions for cLBP in obese patients remains limited. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as potent weight loss agents that may also alleviate chronic musculoskeletal pain. METHODS: Patients newly prescribed GLP-1 RAs for weight loss were recruited from outpatient clinics. Eligible patients had a BMI of 35-50 kg/m2 and cLBP with pain intensity ≥3/10. Exclusion criteria included prior bariatric or lumbar spine surgery and previous GLP-1 RA use. Patients who were prescribed but never started the medication formed a control cohort. At baseline, 3-months, and 6-months, participants completed questionnaires including Brief Pain inventory (BPI), Oswestry Disability index (ODI), and Short Form Survey (SF-12) to measure quality-of-life. Linear mixed models analyzed treatment duration effects. RESULTS: 49 participants were enrolled, with 35 in the GLP-1 RA cohort and 14 in control. To date, 44 have completed 3-month follow-up, and 12 have reached 6-months. GLP-1 RA users showed significant decreases in BMI, pain severity, interference, and disability. Physical and mental-health related quality-of-life appeared to increase but did not reach significance. Compared to control participants, the GLP-1 cohort had a greater median decrease in BPI Pain Severity at 3-months, though this did not reach significance (control: 0, GLP-1: -0.9, p = .37). CONCLUSIONS: Early results suggest that weight loss with GLP-1 RAs may reduce back pain severity, though this ongoing pilot study is limited by its observational nature and small sample size. Future work should investigate possible mechanisms of pain reduction, such as reduced mechanical loading and decreased inflammation.

Fields of Study & Subjects

Musculoskeletal pain and rehabilitation Spine and Intervertebral Disc Pathology Pain Mechanisms and Treatments

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
211–211
Publication date
26 March 2026
Language
EN